Drug reference
Constipation in palliative care ▶BY MOUTH USING ORAL SUSPENSION ▶Child 6–11 years: 5 mL once daily, to be taken at night ▶Child 12–17 years: 5–15 mL once daily, to be taken at night ▶Adult: 5–15 mL once daily, to be taken at night DOSE EQUIVALENCE AND CONVERSION ▶Co-danthrusate suspension contains dantron 50 mg and docusate sodium 60 mg per 5 mL.
PDF page 88
Acute abdominal conditions. acute inflammatory bowel disease. intestinal obstruction. severe dehydration
PDF page 88
Excessive use of stimulant laxatives can cause diarrhoea and related effects such as hypokalaemia. may cause local irritation. rodent studies indicate potential carcinogenic risk CAUTIONS, FURTHER INFORMATION ▶Local irritation Avoid prolonged contact with skin (incontinent patients—risk of irritation and excoriation).
PDF pages 88, 89
→Appendix 1: docusate sodium
PDF page 89
Gastrointestinal disorders. skin reactions. urine orange
PDF page 89
Manufacturers advise avoid—limited information available.
PDF page 89
Manufacturers advise avoid—no information available.
PDF page 89
There can be variation in the licensing of different medicines containing the same drug. Oral suspension CAUTIONARY AND ADVISORY LABELS 14 (urine orange) ▶Co-danthrusate (Non-proprietary) Dantron 10 mg per 1 ml, Docusate sodium 12 mg per 1 ml Co- danthrusate 50mg/60mg/5ml oral suspension sugar free sugar-free | 200 ml P £202.50 DT = £202.50
PDF page 89
5–15 mL once daily, to be taken at night
First-line fragment. Read the complete Indications and Dose section above.
PDF page 88
